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Background.  —  Whether  outcomes  differ  for  women  and  men  after  percutaneous  coronary  inter-
vention (PCI)  for  ST-segment  elevation  myocardial  infarction  (STEMI)  remains  controversial.
Aim. —  To  compare  1-year  outcomes  after  primary  PCI  in  women  and  men  with  STEMI,  matchedCoronary  angioplasty;
Sex
for age  and  diabetes.
Methods.  —  Consecutive  women  with  STEMI  of  <  24  hours’  duration  referred  (August  2007  to  Jan-
uary 2011)  for  primary  PCI  were  compared  with  men  matched  for  age  and  diabetes.  Rates  of
all-cause  mortality,  target  vessel  revascularization  (TVR)  and  major  cardiovascular  and  cere-
brovascular  events  (MACCE)  (death/myocardial  infarction/stroke)  were  assessed  at  1  year.
Abbreviations: ECMO, Extracorporeal membrane oxygenation; LM, Left main; MACCE, Major cardiovascular and cerebrovascular events;
HCA, Out-of-hospital cardiac arrest; PCI, Percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIMI,
hrombolysis in myocardial infarction; TVR, Target vessel revascularization.
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Results.  —  Among  775  consecutive  patients,  182  (23.5%)  women  were  compared  with  182
matched men.  Mean  age  was  69  ±  15  years,  18%  had  diabetes.  Patient  characteristics  were
similar, except  for  lower  creatinine  clearance  (73  ±  41  vs  82  ±  38  mol/L;  P  =  0.041),  more  car-
diogenic shock  (14.8%  vs  6.6%;  P  =  0.017)  and  less  radial  PCI  (81.3%  vs  90.1%;  P  =  0.024)  in  women.
Rates of  1-year  death  (22.7%  vs  18.1%),  TVR  (8.3%  vs  6.0%)  and  MACCE  (24.3%  vs  20.9%)  were
not statistically  different  in  women  (P  >  0.05  for  all).  After  exclusion  of  patients  with  shock
(10.7%) and  out-of-hospital  cardiac  arrest  (6.6%),  death  rates  were  even  more  similar  (11.3%
vs 11.8%;  P  =  0.10).  Female  sex  was  not  independently  associated  with  death  (odds  ratio  1.01,
95% conﬁdence  interval  0.55—1.87;  P  =  0.97).
Conclusion.  —  In  our  consecutive  unselected  patient  population,  women  had  similar  1-year  out-
comes to  men  matched  for  age  and  diabetes,  after  contemporary  primary  PCI  for  STEMI,  despite
having a  higher  risk  proﬁle  at  baseline.









Contexte.  —  Malgré  de  nombreuses  données  disponibles,  l’inﬂuence  du  sexe  sur  le  pronostic  des
patients pris  en  charge  par  angioplastie  coronaire  primaire  (ACP)  pour  un  infarctus  du  myocarde
avec élévation  du  segment  ST  (IDM-ST+)  reste  controversée.
Objectif.  — Comparer  l’évolution  à  un  an  en  fonction  du  sexe  des  patients  pris  en  charge  par
ACP pour  un  IDM-ST+,  après  appariement  des  hommes  pour  l’âge  et  le  diabète.
Méthodes.  — Toutes  les  femmes  adressées  au  Cath-Lab,  d’août  2007  à  janvier  2011,  pour  ACP
d’un IDM-ST+  <  24  heures  ont  été  comparées  aux  hommes  appariés  pour  l’âge  et  le  diabète.
La mortalité  totale,  les  nouvelles  revascularisations  et  les  MACCE  (décès,  IDM,  AVC)  étaient
évaluées  à  12  mois.
Résultats.  — Parmi  775  patients  consécutifs  présentant  un  IDM-ST+,  182  (23,5  %)  femmes  ont
été comparées  à  182  hommes  appariés.  L’âge  moyen  était  de  69  ±  15  ans,  18  %  étaient  diabé-
tiques. Les  caractéristiques  des  patients  étaient  comparables,  à  l’exception  d’une  clairance  de
la créatinine  plus  basse  (73  ±  41  vs  82  ±  38  mol/L  ;  p  =  0,041),  un  taux  de  choc  cardiogénique
plus élevé  (14,8  %  vs  6,6  %  ;  p  =  0,017)  et  un  recours  à  l’abord  radial  plus  rare  (81,3  %  vs  90,1  %  ;
p =  0,024)  chez  les  femmes.  À  un  an,  les  taux  de  décès  (22,7  %  vs  18,1  %),  nouvelle  revascularisa-
tion (8,3  %  vs  6,0  %)  et  MACCE  (24,3  %  vs  20,9  %)  n’étaient  pas  statistiquement  différents  entre
les femmes  et  les  hommes  (p  >  0,05).  Après  exclusion  des  patients  en  choc  (10,7  %)  ou  arrêt
cardiaque pré-hospitalier  (6,6  %),  les  taux  de  mortalité  étaient  même  comparables  (11,3  %  vs
11,8 %  ;  p  =  0,10).  Après  analyse  multivariée  par  régression  logistique,  le  sexe  féminin  n’était
pas indépendamment  associé  avec  le  risque  de  mortalité  (OR  1,01,  CI  0,55—1,87  ;  p  =  0,97).
Conclusion.  —  Dans  notre  population  consécutive  et  non  sélectionnée,  les  femmes  ont  un
pronostic à  un  an  comparable  à  celui  des  hommes  appariés  pour  l’âge  et  le  diabète,  après
angioplastie  primaire  pour  infarctus  du  myocarde  avec  élévation  du  segment  ST,  et  ce  malgré
un proﬁl  clinique  plus  à  risque.






Cardiovascular  diseases  remain  the  leading  cause  of  mor-
tality  among  women  in  Europe  [1],  with  ST-segment
elevation  myocardial  infarction  (STEMI)  being  the  most
acute  complication  of  coronary  heart  disease.  Primary  per-
cutaneous  coronary  intervention  (PCI)  has  been  shown
to  decrease  global  mortality  and  is  the  recommended
reperfusion  therapy  for  STEMI  [2,3].  Various  authors  have
reported  higher  mortality  rates  in  women  than  in  men  pre-
senting  with  STEMI  [4—8].  These  results  may  be  explained
by:
t
aolder  age  at  presentation  in  women;
more  severe  coexisting  conditions  and  more  frequent  car-
diovascular  risk  factors;
worse  clinical  presentation,  especially  a  higher  incidence
of  cardiogenic  shock;
longer  delays  in  diagnosis  and  transfer  to  catheterization
laboratory  due  to  atypical  symptoms;
less  invasive  management  [5,9].The  European  Society  of  Cardiology  guidelines  emphasize
he  need  for  a  homogenous  treatment  strategy  for  women






































































































Although  extensive  data  are  available  comparing  out-
omes  in  women  and  men  after  STEMI,  this  issue  remains
ontroversial,  with  some  authors  reporting  higher  mortal-
ty  rates  and  others  reporting  no  differences  [10,11].  Some
uthors  have  reported  an  excess  of  mortality,  especially  in
ounger  women  [9],  while  others  have  reported  this  in  the
lderly  [7,8].  Moreover,  women  are  less  represented  in  ran-
omized  trials  and  the  sickest  patients  are  often  excluded
rom  these  analyses.
Our  prospective  study  aims  to  add  new  data  to  existing
vidence  on  cardiovascular  outcomes  in  women  undergoing
uccessful  primary  PCI  with  stenting  for  STEMI.  We  com-
ared,  in  a  high-volume  single  centre  in  France,  consecutive
nselected  women  with  men,  after  matching  for  age  and
iabetes,  in  the  modern  reperfusion  era.
ethods
atient population
ll  consecutive  patients  with  ongoing  STEMI,  who  presented
or  primary  PCI  at  the  Pitié-Salpêtrière  University  Hospi-
al  catheterization  laboratory  from  August  2007  to  January
011,  were  eligible  for  the  study.  STEMI  was  deﬁned  by
he  presence  of  symptoms  of  myocardial  ischaemia,  asso-
iated  with  new  electrocardiographic  abnormalities  in  the
T-segment  (elevation  at  the  J  point  of  at  least  0.2  mV  in
eads  V1,  V2  and  V3  and  at  least  0.1  mV  in  other  leads,  in  at
east  two  contiguous  leads)  or  new  left  bundle  branch  block,
ssociated  with  later  elevation  of  cardiac  markers  (creatine
inase  and/or  troponin  I)  at  least  three  times  above  the
pper  limit  of  normal  values.  Clinical  and  angiographic  data
ere  prospectively  recorded  in  the  web-based  MiddleCare
atabase.
According  to  European  guidelines,  primary  PCI  is  the  pre-
erred  strategy  when  the  ﬁrst  medical  contact  to  balloon
nﬂation  time  is  <  120  minutes  [3,12].  The  Pitié-Salpêtrière
niversity  Hospital  is  part  of  the  Paris  STEMI  network  and
s  the  invasive  hub  for  the  southeast  part  of  the  city,  which
epresents  approximately  one-quarter  of  the  Parisian  popu-
ation  [13].  The  French  healthcare  system  uses  ﬁeld  triage
ith  mobile  intensive  care  units,  with  an  on-board  physi-
ian  facilitating  rapid  transfer  to  a  primary  PCI  centre,  while
tarting  antithrombotic  therapy  at  the  same  time.  This  sys-
em  is  predominant  in  Paris  and  is  very  effective,  allowing
rimary  PCI  to  be  the  nearly  exclusive  mode  of  reperfusion
or  STEMI.
All  patients  were  treated  according  to  current  guidelines
ith  aspirin,  a  P2Y12 inhibitor  and  anticoagulant  [3].  The
se  of  glycoprotein  IIb/IIIa  inhibitors  was  left  at  the  discre-
ion  of  the  operator.  Primary  PCI  was  performed  by  radial
ccess  in  the  ﬁrst  intention,  using  mostly  6  French  sheaths,
ith  selective  thrombus  aspiration  (according  to  thrombus
urden)  and  systematic  stent  implantation  (unless  consid-
red  inappropriate  by  the  physician).  Intra-aortic  balloon
ump  counterpulsation  or  extracorporeal  membrane  oxy-
enation  (ECMO)  could  be  used  if  required  in  cardiogenic
hock.
This  study  was  conducted  in  accordance  with  internation-
lly  accepted  recommendations  for  clinical  investigation
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ndpoints
he  primary  endpoint  was  death  from  all-causes  at
 year.  The  secondary  endpoints  were  cardiovascular  death,
yocardial  infarction,  target  vessel  revascularization  (TVR)
nd  the  composite  of  major  cardiovascular  and  cerebrovas-
ular  events  (MACCE)  (comprising  cardiovascular  death,
yocardial  infarction  and  stroke)  at  1  year.
We  blindly  selected  a  population  of  men  matched  to  the
emale  population  for  age  group  (age  ≤  45,  45—54,  55—64,
5—74  and  >  75  years)  and  the  presence  of  diabetes  mellitus.
One-year  outcomes  were  compared  in  women  versus
en  (all)  and  versus  men  (matched).  Mortality  analy-
es  were  also  performed  in  pre-speciﬁed  patient  subgroups:
ge  ≤  85  years;  patients  without  cardiogenic  shock  or
ut-of-hospital  cardiac  arrest  (OHCA);  patients  who  sur-
ived  >  48  hours;  and  hospital  survivors.
eﬁnitions
ardiogenic  shock  was  deﬁned  as  systolic  blood  pres-
ure  <  90  mmHg  for  at  least  30  minutes  or  the  need  to  use
ntravenous  inotropes  to  maintain  a systolic  blood  pres-
ure  >  90  mmHg,  with  end-organ  hypoperfusion  at  admission
nd  before  PCI.  Multivessel  disease  was  deﬁned  by  stenosis
f  the  left  main  artery  or  the  presence  of  at  least  one  signif-
cantly  narrowed  coronary  vessel  (left  anterior  descending,
ircumﬂex  or  right  coronary  artery)  in  addition  to  the  culprit
essel.
Death  was  deﬁned  as  death  from  any  cause  and  was
valuated  at  1  year  of  follow-up.  Myocardial  infarction  was
eﬁned  as  recurrent  chest  pain  and/or  electrocardiogram
hanges  with  at  least  one  of  the  following  criteria:  cre-
tine  kinase  ≥  2  times  the  upper  limit  of  normal,  with
 rise  of  >  50%  of  the  previous  value,  associated  with  a
ositive  troponin  I  test;  and  the  appearance  of  new  left
undle  branch  block  or  new  Q  waves.  Stroke  was  deﬁned
s  an  acute  neurological  deﬁcit  lasting  >  24  hours,  as  classi-
ed  by  a  physician,  with  supporting  information,  including
rain  images  and  neurological/neurosurgical  evaluation.
ACCE  was  the  composite  of  cardiovascular  death,  non-
atal  myocardial  infarction  and  non-fatal  stroke.  Bleeding
omplications  were  assessed  according  to  the  Bleeding  Aca-
emic  Research  Consortium  classiﬁcation  [14]. Creatinine
learance  was  assessed  using  the  Cockcroft—Gault  formula.
utcomes
n-hospital  outcomes  were  based  on  medical  examina-
ion,  medical  records,  electrocardiography  and  troponin  I
oncentration.  One-year  clinical  outcomes  were  obtained
y  telephone  call  by  clinic  research  associates,  by  medi-
al  consultation  or  from  rehospitalization  medical  reports.
n  the  absence  of  direct  contact  with  the  patient,  survival
tatus  was  checked  in  the  birth  City  Hall  registry.
tatistical analysesategorical  variables  are  expressed  as  frequencies
nd  percentages;  continuous  variables  are  expressed
s  means  ±  standard  deviations;  symptom  onset-to-
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range.  Categorical  variables  were  compared  using  Fisher’s
exact  test  and  continuous  variables  were  compared  using
analysis  of  variance.  A  signiﬁcance  level  of  0.05  was
assumed  for  the  statistical  tests.  Kaplan—Meier  survival
curves  were  created  using  GraphPad  Prism,  version  5.01
for  Windows  (GraphPad  Software,  San  Diego,  CA,  USA).
Independent  predictors  of  death  at  1  year  were  assessed
by  multivariable  logistic  regression  analysis  on  the  whole
population,  using  Statview  software,  version  5.0  (SAS
Institute,  Inc.,  Cary,  NC,  USA).
Results
Nine  hundred  and  ﬁfty-three  patients  were  referred  to
our  institution  over  42  months  for  primary  PCI  for  STEMI.
Among  them,  141  (14.8%)  patients,  including  51  women,
did  not  undergo  primary  PCI  (medical  treatment  [n  =  58],
emergency  coronary  artery  bypass  graft  [n  =  10],  other  diag-
nosis  [n  =  64]  —  including  perimyocarditis  [n  =  10]  and  stress
cardiomyopathy  [n  =  12]  —  and  death  in  catheterization  lab-
oratory  [n  =  9]).  Thirty-seven  (3.9%)  patients,  including  11
women,  had  balloon  angioplasty  without  stenting  and  were
excluded.
Baseline characteristics
During  the  study  period,  775  STEMI  patients  were  treated
by  primary  PCI  with  stenting  at  the  Pitié-Salpêtrière  Hospi-
tal;  182  (23.5%)  were  women  and  593  (76.5%)  were  men.
Baseline  characteristics  are  shown  in  Table  1.  In  the  total
population,  the  mean  age  was  63  ±  14  years,  with  a  9-year
delayed  occurrence  of  STEMI  in  women  versus  men  (P  <  0.05)
(Fig.  1).  Diabetes  was  as  frequent  in  women  as  in  men
(Table  1).  Women  were  less  likely  to  be  smokers  or  to  have  a
history  of  myocardial  infarction;  however,  they  had  a higher
prevalence  of  hypertension  and  lower  renal  function.  In
women,  cardiogenic  shock  occurred  twice  as  often  at  admis-
sion,  and  radial  access  (trend)  and  manual  thrombectomy
were  used  less  often  during  PCI  than  in  men.










After  matching,  baseline  characteristics  became  similar
n  women  and  men  (matched),  except  for  lower  creatinine
learance  (73  ±  41  mol/L  vs  82  ±  38  mol/L;  P = 0.041)  and
 more  than  doubled  rate  of  cardiogenic  shock  (14.8%  vs
.6%;  P  =  0.017)  at  initial  presentation  in  women.  Radial
ccess  for  PCI  was  less  frequent  in  women  (81.3%  vs  90.1%;
 =  0.024).
Evidence-based  therapy  was  widely  used  and  similar  in
en  (matched)  versus  women  at  discharge  (Table  2).
ardiovascular outcomes at 1 year
ne-year  follow-up  data  were  available  for  99.7%  (n  = 363)
f  the  matched  population  and  for  97.7%  (n  =  757)  of  the
hole  population.  Results  are  shown  in  Table  3.  At  1  year,
ortality  was  signiﬁcantly  higher  in  women  than  in  men
22.7%  vs  15.3%;  P  =  0.024)  in  this  unselected  patient  pop-
lation;  however,  this  difference  did  not  remain  signiﬁcant
fter  adjustment  (22.7%  vs  18.1%;  P  =  0.30).  A  similar  ﬁnding
as  observed  for  cardiovascular  mortality.
In-hospital  death  accounted  for  most  of  the  mortality
t  1  year  in  women  (19.8%)  and  in  men  before  matching
11.2%)  and  after  matching  (13.7%)  (Fig.  2).  Bleeding  rates
ere  similar,  with  transfusion  occurring  in  5.1%  of  men
matched)  vs  7.0%  of  women  (P  =  0.29).  Cardiogenic  shock
15.4%)  was  associated  with  high  in-hospital  mortality:  81.5%
f  women  in  cardiogenic  shock  at  admission  died  during  hos-
ital  stay  compared  with  75.0%  of  men  (matched)  (P  =  0.68).
e  observed  a  more  pronounced  steady  increase  in  mortality
ccording  to  age  in  women  compared  with  in  men  (P  <  0.05)
Fig.  3).  Considering  the  other  secondary  endpoints  (myocar-
ial  infarction,  TVR,  MACCE),  no  signiﬁcant  differences  were
bserved  in  the  whole  population  or  after  matching.
ubgroup analyses
ifty  (6.5%)  of  the  patients  were  aged  >  85  years,  119  (15.4%)
ad  cardiogenic  shock  or  OHCA  at  admission,  54  (7.0%)
ied  within  48  hours,  and  102  (13.2%)  died  during  hospi-
alization.  Four  subgroup  analyses  were  performed  in  the
atched  population.  At  1  year:  after  exclusion  of  the  elderly
aged  >  85  years),  total  mortality  was  17.9%  in  women  vs
igure 2. Kaplan—Meier curve of 1-year mortality according to
ex.
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Table  1  Baseline  characteristics.
Men  (all)
(n  =  593)
Men  (matched)
(n  =  182)
Women
(n  =  182)
Pa Pb
Age  (years)  61  ±  13  69  ±  15  70  ±  15  <  0.001  0.61
Body  mass  index  (kg/m2)  27  ±  12  26  ±  4  27  ±  13  0.86  0.62
Risk  factors  (%)
Diabetes  mellitus  18.2  18.1  18.1  0.10  0.10
Dyslipidaemia  39.3  39.6  34.6  0.30  0.39
Current  smoker 45.2  25.8  26.9  <  0.001  0.91
Hypertension  42.3  52.7  56.0  0.001  0.60




10.1  8.2  4.9  0.036  0.29
PCI  (%)  11.1  9.9  7.1  0.21  0.45
CABG  (%) 3.4  3.3  2.2  0.62  0.75
Stroke  (%) 3.5  2.7  2.2  0.48  0.10
Creatinine  clearance
(mol/L)





4  ±  4  4  ±  7  4  ±  5.5  0.72  0.86
STEMI  <  12  hours  (%)  82.3  80.9  83.6  0.82  0.67
Cardiogenic  shock  (%)  7.9  6.6  14.8  0.009  0.017
OHCA  (%)  9.8  7.1  6.0  0.14  0.83
PCI  (%)
Radial  PCI  87.4  90.1  81.3  0.05  0.024
Multivessel  disease  51.9  48.9  46.7  0.24  0.75
Culprit  lesion  0.16  0.27
Left  main  2.5  3.3  3.3
LAD  46.0  48.9  40.7
Circumﬂex  18.5  16.5  14.3
RCA  32.9  30.8  41.2
Stent
Number  1.6  ±  0.8  1.6  ±  0.9  1.5  ±  0.8  0.64  0.42
Total  length  (mm)  28  ±  18  29  ±  20  27  ±  15  0.38  0.32
Diameter  (mm)  2.9  ±  0.5  2.8  ±  0.5  2.8  ±  0.4  0.005  0.38
Drug-eluting  (%) 25.6  25.3  21.4  0.28  0.46
Post-PCI  TIMI  3  ﬂow  (%)  93.4  93.4  90.7  0.25  0.44
Adjunctive  therapy  (%)
Glycoprotein  IIb/IIIa
inhibitor
70.7  65.4  63.2  0.07  0.74
Prehospital  thrombolysis  2.9  0.5  2.2  0.80  0.37
Thrombectomy  38.1  29.7  28.6  0.022  0.91
IABP  3.5  2.2  3.8  0.82  0.54
ECMO  5.6  2.2  3.8  0.45  0.54
Post-PCI
Peak  troponin  I  (g/L)  121  ±  261  105  ±  139  83  ±  101  0.06  0.08
Any  bleeding  (%)  6.4  7.1  7.1  0.73  0.10
Length  of  hospital  stay
(days)
7 ±  13  8  ±  17  7  ±  7  0.43  0.26
Data are expressed as mean ± standard deviation or %; CABG: coronary artery bypass graft; CAD: coronary artery disease; ECMO:
extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump counterpulsation; LAD: left anterior descending; OHCA:
out-of-hospital cardiac arrest; PCI: percutaneous coronary intervention; RCA: right coronary artery; STEMI: ST-segment elevation
myocardial infarction; TIMI: Thrombolysis In Myocardial Infarction.
a Men (all) versus women.
b Men (matched) versus women.
c Median ± interquartile range.
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Table  2  Discharge  therapy.
Treatment  %  of  patients  P
Men  (matched)  Women
Aspirin  100  99.3 0.47
Clopidogrel  77.8  79.0  0.89
Prasugrel  20.3  21.0  0.89
Statin  96.1  97.8  0.51
Beta-blocker  88.2  86.2  0.73
ACEI/ARB  83.0  82.6  0.10
Proton  pump  inhibitor  85.6  82.6  0.52
Vitamin  K  antagonist  5.9  3.6  0.42
UFH/LMWH  5.9 5.1 0.80
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin






















16.0%  in  men  (P  =  0.60);  after  exclusion  of  patients  pre-
senting  with  cardiogenic  shock  or  OHCA,  total  mortality  was
11.4%  in  women  and  11.8%  in  men  (P  =  0.93);  after  exclusion
of  the  sickest  patients  who  died  within  the  ﬁrst  48  hours
of  hospitalization,  1-year  mortality  decreased  to  11.3%  in
women  vs  12.9%  in  men  (P  =  0.69);  and  limiting  the  analyses
to  hospital  survivors  (n  =  302),  3.4%  of  women  and  5.1%  of
men  died  (P  =  0.48)  (Fig.  4A—D).  Focusing  on  secondary  end-
points,  there  were  also  no  differences  between  women  and
men  in  each  subgroup  analysis  (data  not  shown).
Logistic regression analysis
After  multivariable  analysis,  sex  was  not  independently
associated  with  mortality  at  1  year  (odds  ratio  1.01,  95%
conﬁdence  interval  0.55—1.87;  P  =  0.97)  (Table  4).  Inde-
pendent  predictors  of  death  were  age,  cardiogenic  shock,
OHCA  and  troponin  (peak),  whereas  creatinine  clearance,
drug-eluting  stent  and  post-PCI  thrombolysis  in  myocardial
infarction  (TIMI)  3  ﬂow  were  predictive  of  survival.Discussion
Our  study  found  that,  in  an  all-comers  population  of  STEMI




Table  3  One-year  outcomes.
Men  (all)
(n  =  593)
Men  
(n  =  1
Death  15.3  18.1  
Cardiovascular  death  13.2  14.3  
In-hospital  death  11.2  13.7  
Myocardial  infarction  4.9  5.5  
Target  vessel  revascularization  9.9  6.0  
MACCE  18.8  20.9  
Data are expressed as %; MACCE: major cardiovascular and cerebrovas
a Men (all) versus women.
b Men (matched) versus women.igure 3. Mortality rates by age group in women and men (all and
atched).
ates  of  1-year  all-cause  and  cardiovascular  mortality  were
igher  in  women  than  in  men.  Indeed,  women  were  older,
ad  more  cardiovascular  risk  factors  and  coexisting  con-
itions,  presented  with  more  severe  STEMI  (twice  more
ardiogenic  shock)  and  had  less  effective  management.
owever,  after  adjustment  for  age  and  diabetes  melli-
us,  mortality  rates  were  no  longer  signiﬁcantly  different
etween  sexes.  Interestingly,  the  increased  mortality  rate
ppeared  more  pronounced  in  elderly  women  compared
ith  that  in  elderly  men.  Furthermore,  after  exclusion  of
he  sickest  patients  (often  excluded  from  study  in  this
etting)  —  either  those  who  initially  presented  with  cardio-
enic  shock  and/or  OHCA  or  those  who  died  within  the  ﬁrst
8  hours  —  1-year  death  rates  appeared  even  lower  in  women
ompared  with  in  men.  A  more  detailed  analysis  of  these
esults  suggests  that  women  may  have  higher  in-hospital
ortality  rates  with  subsequent  better  1-year  outcomes
fter  hospital  discharge.  Finally,  female  sex  was  not  an  inde-
endent  predictor  of  mortality  after  multivariable  analysis.
In  our  patient  population,  1-year  death  occurred  in  one
oman  out  of  ﬁve.  Some  previous  studies  have  reported
ower  event  rates  during  follow-up  [7,15], while  other  reg-




(n =  182)
Pa Pb
22.7  0.024  0.30
19.9  0.031  0.17
19.8  0.004  0.16
3.3  0.54  0.44
8.3  0.57  0.42
24.3  0.11  0.45
cular events.
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Table  4  Logistic  regression  analysis  for  mortality.
Variables  Odds  ratio  95%  CI  P
Female  sex  1.01  0.55—1.87  0.97
Age  (per  1-year  year)  1.03  1.01—1.06  0.015
Diabetes  mellitus  1.58  0.83—2.99  0.17
History  of  myocardial  infarction  1.91  0.88—4.13  0.10
Creatinine  clearance  (per  unit  increase)  0.98  0.97—0.99  <  0.001
Cardiogenic  shock 11.69 5.43—25.18 <  0.001
OHCA  7.82 3.55—17.23 <  0.001
Radial  PCI 0.67 0.35—1.30 0.24
Multivessel  disease  1.23  0.69—2.20  0.48
Number  of  stents  (per  unit  increase)  1.31  0.95—1.80  0.10
Drug-eluting  stent  0.23  0.08—0.61  0.004
Post-PCI  TIMI  3  ﬂow  0.45  0.21—0.99  0.047
Troponin  (peak)  1.00  1.00—1.00  0.008




igure 4. Kaplan—Meier 1-year mortality curves in four different subg
hock or out-of-hospital cardiac arrest (OHCA) at admission. C. Patients roups. A. Patients aged < 85 years. B. Patients without cardiogenic
















































MSex  and  outcomes  after  STEMI  PCI  
This  high  rate  may  be  explained  by  the  unselected  nature  of
our  study  population,  without  any  patient  exclusion,  and  the
particularly  high-risk  proﬁle  (9.8%  OHCA  and  5.6%  ECMO  in
men;  14.8%  cardiogenic  shock  in  women).  Patients  admit-
ted  in  cardiogenic  shock  account  for  most  of  the  in-hospital
mortalities  (81.5%  of  women  and  75.0%  of  men  [matched]
with  cardiogenic  shock  died  during  hospital  stay).  Indeed,  as
our  institution  is  a  reference  centre,  with  24/7  primary  PCI
facilities  and  on-site  cardiac  surgery  availability  (including
ECMO),  the  most  severe  patients  are  preferentially  referred
to  our  department.  Thus,  performing  subgroup  analyses  may
bring  a  better  understanding  and  a  fairer  comparison  of
sex  differences.  STEMI  women  and  men  without  cardio-
genic  shock  had  similar  in-hospital  mortality  rates  (9.0%  vs
9.4%,  P  =  0.10).  After  exclusion  of  these  sickest  patients,  the
1-year  mortality  rate  dropped  as  low  as  11—12%  (after  exclu-
sion  of  patients  with  initial  OHCA  and/or  cardiogenic  shock
or  those  who  died  within  48  hours  after  admission).  Consid-
ering  hospital  survivors  only,  1-year  mortality  appeared  very
low,  as  reported  previously,  especially  in  women  (3.4%  in
women  vs  5.1%  in  men)  [17].
At  baseline,  women  had  a  higher  risk  proﬁle  in  our  popu-
lation:  they  were  older,  more  often  had  coexisting  conditions
and  presented  twice  as  often  with  cardiogenic  shock  —  an
observation  widely  reported  in  the  literature  [2,5]. Fur-
thermore,  radial  access  PCI  was  less  frequent  and  manual
thrombectomy  was  used  less  often.  These  ﬁndings  are  in
line  with  most  of  the  published  studies  in  this  setting,  and  it
is  generally  admitted  that  women  have  a  higher  risk  proﬁle
at  admission  and  more  limited  access  to  PCI  [18—22].
Age  is  a  constant  confounding  factor  when  considering
the  outcomes  of  men  versus  women  after  STEMI  [4—11]. It
is  also  well  known  that  mortality  after  STEMI  is  inﬂuenced
by  many  factors,  including  age  and  diabetes  mellitus  [12].
After  matching,  outcomes  rates  did  not  remain  signiﬁcantly
different  in  women  compared  with  in  men.  In  addition,
multivariable  analysis  found  that  female  sex  was  not  an
independent  predictor  of  adverse  outcome,  as  reported
elsewhere  [16,18,20].  Our  results  conﬁrm  the  slightly  higher
in-hospital  mortality  rate  in  women  reported  by  other
authors  [7,10,18,23],  and  the  particularly  high  mortality
rate  in  very  elderly  women  [8,24].  Beyond  the  higher  risk
proﬁle,  an  intrinsic  risk  associated  with  PCI  in  women  has
also  been  suggested  [7]  —  a  hypothesis  we  could  not  con-
ﬁrm  in  our  study;  PCI  success  rates  (post-PCI  TIMI  3  ﬂow)
were  similar  and  even  if  radial  PCI  was  used  less  often,
bleeding  complications  and/or  transfusions  rates  were  simi-
lar  in  women  and  men  (matched).  Conversely,  the  long-term
prognosis  may  be  even  better  in  women  than  in  men,  as
previously  described  [10,23].
This  study  has  several  limitations  that  should  be  men-
tioned.  First,  this  was  a  single  centre  non-randomized
registry  study.  Our  observational  study  is  prone  to  bias
linked  to  unmeasured  factors,  and  may  only  reﬂect  the
activity  of  our  experienced  PCI  centre.  Conversely,  the  con-
secutive  unselected  nature  of  the  patient  population  is
one  of  the  strengths  of  our  study,  which  reﬂects  real-life
STEMI  management.  Second,  adjusting  for  multiple  varia-
bles  resulted  in  similar  outcomes,  but  we  cannot  exclude
non-assessed  confounders.  In  particular,  due  to  the  inclusion
of  all  the  women  in  the  analyses,  age  distribution  could  not





nfortunate  that  the  well-established  STEMI  mortality  risk
cores  (TIMI,  GRACE)  [25,26]  could  not  be  assessed.  How-
ver,  the  logistic  regression  analysis  included  all  the
ariables  (except  heart  rate)  from  these  scores,  and  took
nto  account  the  weight  of  each  variable  affecting  the  prog-
osis  of  STEMI  patients.  Finally,  the  statistical  power  of
nalyses  conducted  on  such  a  population  sample  size  is  insuf-
cient  to  enable  any  deﬁnitive  conclusion  to  be  drawn,  and
an  only  generate  hypotheses.
Another  strength  of  our  study  is  that  our  patients  were
ncluded  in  the  modern  era  of  reperfusion,  with  wide  drug-
luting  stent  use,  thrombus  aspiration  in  one-quarter  of
atients  and  recent  potent  medical  therapy.  Thus,  these
ecent  data  reﬂect  more  precisely  the  current  setting  of
TEMI  treatment  in  women  than  most  previous  studies,
hich  were  conducted  before  these  major  achievements  in
TEMI  management.
onclusions
ooking  at  unselected  STEMI  patients  sent  to  the  cath-
terization  laboratory  for  primary  PCI  with  stenting,  we
bserved  a  higher  mortality  rate  in  women  than  in  men,
hich  disappeared  after  adjustment  for  age  and  diabetes.
otably,  women  had  a  trend  for  higher  in-hospital  mortality
n  the  one  hand,  with  fewer  long-term  adverse  events  on  the
ther.  We  conclude  that  the  excess  of  mortality  observed  in
omen  undergoing  primary  PCI  for  STEMI  is  mainly  driven  by
 higher  risk  proﬁle  at  baseline,  including  older  age  and  a
orse  clinical  presentation.
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